About Us

Who we are

BioSpeedia is a biotechnology company specializing in the development and production of rapid diagnostic tests for infectious diseases.

It was founded in 2011 by two scientists from the Institut Pasteur : Evelyne Begaud and Yves Germani. The Institut Pasteur, created in 1888, is the first non-profit foundation and is the source of 10 Nobel Prizes. Evelyne Begaud is the current president of BioSpeedia, and Yves Germani is its chief scientific officer.

Our partners

In connection with the Covid-19 pandemic and the implementation of regular screenings with the use of antigenic tests, BioSpeedia has signed a strategic and technological partnership with SICPA to offer services allowing safe travel in addition to our range of screening products.

Still in connection with the production of antigenic tests for the detection of Covid-19 infection, an industrial partnership has also been signed with Delpharm Biotech, which manufactures our rapid test in France. We have a fully automated French production line for “lateral flow” tests.

Sales and worldwide distribution of BioSpeedia, product registration, liaison with regulatory authorities, logistics and shipping are handled by our distribution arm BioVitess Ltd., a sister company based in the UK.

BioSpeedia also has subsidiaries in the United States with BioSpeedia LLC and in Switzerland with BioSpeedia International SARL.


We are a spin-off from Institut Pasteur and have a license giving us access to the main reagents.


BioSpeedia manufacture in France at the Delpharm Biotech factory in Lyon and will have soon the first and only French fully automated production line for “lateral flow” testing.


BioSpeedia has partnered with the CHU de St Etienne for the design and validation of rapid tests.


BioSpeedia is partnering with SICPA®️ in developing a secured and certified health pass featuring COVID-tests results to allow secured traveling.

Company History

  • Founded in 2011

    The establishment of BioSpeedia

    After spending 3 decades at Institut Pasteur, Yves Germani and Evelyne Begaud, establish the Company as the official spin-off from the premier French Institute.

  • 2014

    Grant from Aide au Partenariat Technologique

  • 2017

    Developed fast and accurate lateral flow diagnostic kit to detect Neisseria meningitidis

    Developed a diagnostic kit to rapidly detect bacterial meningitis using spinal fluid and subsequently using urine samples.

  • 2020

    Received CE Mark for our SARS-CoV-2 rapid antibody test kit

    COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to SARS-CoV-2 coronavirus in human fingertip blood samples

  • 2020

    Seal of Excellence from H2020

    For COVID-19 Response

  • 2020

    Received CE Mark for our SARS-CoV-2 rapid antigen test kit

    Covid-19Speed-Antigen Test is a colloidal gold enhanced double antibody sandwich immunoassay for qualitative determination of SARS-CoV-2 antigen in nasopharyngeal swabs.

  • 2022

    Received CE mark for our Covid-19 self-test kits

    BioSpeedia COVID19 Nasal AUTOTEST and BioSpeedia® Autotest COVID-19 tests are intended to detect a specific antigen of SARS-CoV-2 in a nasal swab sample. These are self-tests, so they can be used by the patients themselves.